Chronic Spontaneous Urticaria
Chronic Spontaneous Urticaria
Advertisement
Cailin ConnerChronic Spontaneous Urticaria | October 15, 2024
Urticaria raises the risk of ADHD, bipolar disorder, and schizophrenia.
Read More
Cailin ConnerChronic Spontaneous Urticaria | October 3, 2024
Omalizumab is a safe and effective long-term treatment for CSU.
Cailin ConnerChronic Spontaneous Urticaria | September 18, 2024
Nearly 50% of patients with chronic spontaneous urticaria are atopic, with atopy linked to increased risk of dermatographism,
Cailin ConnerChronic Spontaneous Urticaria | September 17, 2024
A recent study demonstrated significant associations between acute urticaria and cardiovascular comorbidities.
Cailin ConnerChronic Spontaneous Urticaria | September 18, 2024
Autoimmune mast cell activation test shows promise as a diagnostic tool for chronic spontaneous urticaria.
Cailin ConnerChronic Spontaneous Urticaria | September 9, 2024
Omalizumab treatment in CSU patients leads to significant changes in T-cell subpopulations.
Cailin ConnerChronic Spontaneous Urticaria | September 9, 2024
Patients with both asthma and chronic urticaria have more severe allergic responses.
Cailin ConnerChronic Spontaneous Urticaria | September 9, 2024
Omalizumab effectively reduces symptoms in CSU patients, but a 300 mg dose is recommended.
Cailin ConnerChronic Spontaneous Urticaria | September 9, 2024
A systematic review found that biologic omalizumab is cost-effective for treating H1 antihistamine–refractory CSU.
Cailin ConnerChronic Spontaneous Urticaria | August 28, 2024
According to a recent study, serum zonulin levels had a significant correlation with the urticaria activity score
Cailin ConnerChronic Spontaneous Urticaria | August 27, 2024
Eosinophil/neutrophil/platelet/basophil-to-lymphocyte ratios did not significantly change during 6 months of omalizumab.
Cailin ConnerChronic Spontaneous Urticaria | August 14, 2024
Autologous serum skin test status positivity, comorbid allergic diseases are associated with early response to omalizumab.
Cailin ConnerChronic Spontaneous Urticaria | August 2, 2024
Omalizumab updosing is commonly needed within the first 3 months of treatment for patients with severe CSU.
Cailin ConnerChronic Spontaneous Urticaria | August 1, 2024
Stem cell factor expression was significantly elevated in both the lesional and nonlesional skin of patients with CSU.
Cailin ConnerChronic Spontaneous Urticaria | July 31, 2024
Elevated serum orexin-A levels are associated with poorer sleep quality in patients with chronic spontaneous urticaria.
Cailin ConnerChronic Spontaneous Urticaria | July 31, 2024
Low total immunoglobin E levels, high systemic inflammation response are predictors of poor response to omalizumab.
Cailin ConnerChronic Spontaneous Urticaria | July 30, 2024
A recent study showed positive anti-thyroid peroxidase is a significant risk factor for acute urticaria progression.
Cailin ConnerChronic Spontaneous Urticaria | July 10, 2024
Patients with chronic inducible urticaria respond well to antihistamines and omalizumab.
Cailin ConnerChronic Spontaneous Urticaria | July 9, 2024
A Danish cohort study found that individuals diagnosed with urticaria had a significantly increased risk of cancer.
Cailin ConnerChronic Spontaneous Urticaria | July 8, 2024
Higher neutrophil-lymphocyte ratio and systemic immune-inflammation index may indicate the transition from acute to CU.
Advertisement
Advertisement
Advertisement
Latest News

October 22, 2024